Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.36 |
| ▸ | PLAU | P00749 | 4/20 | 0.35 |
| ▸ | PLAT | P00750 | 2/20 | 0.35 |
| ▸ | PLG | P00747 | 3/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 2/20 | 0.31 |
| ▸ | SLC8A1 | P32418 | 1/20 | 0.31 |
| ▸ | MMP1 | P03956 | 1/20 | 0.31 |
| ▸ | MMP13 | P45452 | 1/20 | 0.31 |
| ▸ | QPCT | Q16769 | 1/20 | 0.31 |
| ▸ | QPCTL | Q9NXS2 | 1/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2648632 | 0.83 | PLAU (0.43) | ADORA3SLC6A3PLAUPLATSMN1; SMN2 | |
| SCHEMBL973472 | 0.76 | NPSR1 (0.33) | PLAUPLATNPSR1CNR2SLC8A1 | |
| SCHEMBL14026302 | 0.73 | ADAMTS5 (0.50) | ADORA3SLC6A3SMN1; SMN2MMP1 | |
| SCHEMBL16004927 | 0.69 | CCR5 (0.49) | SMN1; SMN2CNR2 | |
| SCHEMBL2650487 | 0.69 | ADORA3 (0.39) | ADORA3SLC6A3PLAUPLATPLG | |
| SCHEMBL2649270 | 0.68 | ADORA3 (0.50) | ADORA3SLC6A3SMN1; SMN2QPCTQPCTL | |
| SCHEMBL2648013 | 0.68 | ADORA3 (0.46) | ADORA3SLC6A3NLRP3SMN1; SMN2QPCT | |
| SCHEMBL27618200 | 0.66 | MMP1 (0.46) | NPSR1SMN1; SMN2MMP1MMP13HSD11B1 | |
| SCHEMBL27859234 | 0.65 | SMN1; SMN2 (0.32) | SMN1; SMN2 | |
| SCHEMBL2333945 | 0.65 | ALDH1A1 (0.39) | NPSR1SMN1; SMN2CNR2MMP1MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7582769-B2 | Dicycloalkyl urea glucokinase activators | NOVO NORDISK A/S (DK) | 2009-09-01 | — | — | US | disclosed |
| US-20090118501-A1 | Dicycloalkyl Urea Glucokinase Activators | NOVO NORDISK A/S (DK) | 2009-05-07 | — | — | US | disclosed |
| EP-1904466-A1 | DICYCLOALKYL UREA GLUCOKINASE ACTIVATORS | Novo Nordisk A/S (DK) | 2008-04-02 | — | — | EP | disclosed |
| WO-2007006760-A1 | DICYCLOALKYL UREA GLUCOKINASE ACTIVATORS | NOVO NORDISK A/S (DK) | 2007-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118501-A1 | Dicycloalkyl Urea Glucokinase Activators | GCK, GCKR, UCK2 | ADORA3 3095/4885SLC6A3 3145/4885PLAU 405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.